Recruiting studies: Fgfr Gene Alterations

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Blad
Phase 2 · 46 location(s) · Tyra Biosciences, Inc · NCT06995677 NCCH2006/MK010 Trial (FORTUNE Trial)
Phase 2 · 7 location(s) · National Cancer Center, Japan · NCT04962867 Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
Phase 1 · 4 location(s) · Tyra Biosciences, Inc · NCT06160752 Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With
Phase 1 · 16 location(s) · Tyra Biosciences, Inc · NCT06915753 A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metasta
Phase 2 · 109 location(s) · Sameek Roychowdhury · NCT06906562 Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Gro
Phase 2 · 23 location(s) · Spanish Oncology Genito-Urinary Group · NCT06511648 Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
Phase 2 · 15 location(s) · Tyra Biosciences, Inc · NCT07265947

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.